Biodesix, Inc.
BDSX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.05 | 0.78 | -0.01 |
| FCF Yield | -26.15% | -30.40% | -50.09% | -21.26% |
| EV / EBITDA | -8.01 | -5.00 | -1.66 | -3.44 |
| Quality | ||||
| ROIC | -41.23% | -62.66% | -70.59% | -86.82% |
| Gross Margin | 78.17% | 73.50% | 62.96% | 44.01% |
| Cash Conversion Ratio | 1.13 | 0.44 | 0.69 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.12% | -3.43% | -5.69% | 30.45% |
| Free Cash Flow Growth | -12.95% | 5.31% | -57.64% | -30.70% |
| Safety | ||||
| Net Debt / EBITDA | -1.22 | -0.93 | 0.22 | 0.64 |
| Interest Coverage | -4.18 | -4.34 | -6.27 | -9.08 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 9.29 | 10.11 | 10.52 |
| Cash Conversion Cycle | -7.40 | 14.20 | 41.03 | 39.29 |